Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease.
Bernd MetznerJutta WelzelThomas H MüllerJochen CasperChristoph KimmichEduard K PetershofenAndrea RenzelmannBernd RosienRuth TholeAndreas VossKay WillbornClaus Henning KöhnePublished in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2021)
Sustained long-term remissions can be achieved in patients with early relapse of DLBCL following ASCT in a second or third treatment line, particularly in patients with low- and low-intermediate-risk IPI, following radiotherapy of residual disease after ASCT. Further investigations are required to clarify which patients need an alternative therapy (potentially CAR T‑cells or allogeneic transplantation).
Keyphrases
- stem cell transplantation
- high dose
- diffuse large b cell lymphoma
- locally advanced
- low dose
- end stage renal disease
- early stage
- epstein barr virus
- ejection fraction
- cell therapy
- newly diagnosed
- chronic kidney disease
- radiation induced
- bone marrow
- free survival
- peritoneal dialysis
- prognostic factors
- hematopoietic stem cell
- combination therapy
- smoking cessation